Recruiting

NCT Number: NCT07384897

Immune Cells Role in Lung Cancer and Their Use in Anticancer Immunotherapies and Inflammatory Lung Disease

This study aims to better understand the role of immune system cells in lung diseases such as lung cancer, sarcoidosis, and chronic obstructive pulmonary disease (COPD).

The investigators are studying how these immune cells can sometimes help the body defend itself, but in other cases may contribute to cancer growth or long-term lung inflammation.

Although recent treatments like immunotherapy have improved cancer care, only a small proportion of patients currently benefit from these therapies. One goal of this research is to understand why some patients do not respond or develop resistance to treatment.

The knowledge gained from this study may help researchers develop more effective and personalized treatments for people with lung diseases in the future.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Lung Cancer (Diagnosis) Bronchial Neoplasms Carcinoma, Bronchogenic Carcinoma, Non-Small-Cell Lung Chronic Disease Chronic Obstructive Pulmonary Disease Disease Disease Attributes Hemic and Lymphatic Diseases Hypersensitivity Hypersensitivity, Delayed Immune Dysregulation Immune System Diseases Immunotherapy Resistance Inflammation Lung Diseases Lung Diseases, Obstructive Lung Neoplasms Lymphatic Diseases Lymphoproliferative Disorders Neoplasms Neoplasms by Site Pathologic Processes Pathological Conditions, Signs and Symptoms Pulmonary Disease, Chronic Obstructive Respiratory Tract Diseases Respiratory Tract Neoplasms Sarcoidosis Thoracic Neoplasms

Age range

Up to 80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Cliniques universitaires saint Luc

Brussels, 1200, Belgium

Location status: Recruiting

Location contact

Delphine Hoton, MD

SUB_INVESTIGATOR

Frank Aboubakar Nana, MD; PhD

CONTACT

[email protected]

0032 2 764 85 19

Frank Aboubakar Nana, MD; PhD

PRINCIPAL_INVESTIGATOR

Kim Henquin, Study nurse

CONTACT

[email protected]

0032 2 764 42 26

Valerie Lacroix, MD; PhD

SUB_INVESTIGATOR

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Diagnosis of lung cancer
Presence of precancerous lung lesions
Patients with a chronic inflammatory lung disease (sarcoidosis or chronic obstructive pulmonary disease [COPD]) prior to any treatment
Control group: individuals without known lung disease
Children and adolescents weighing ≥ 10 kg with genetically confirmed chronic granulomatous disease (CGD)
Adults scheduled to undergo orthopedic surgery during which a bone marrow sample will be collected

Exclusion criteria

Systemic corticosteroid therapy > 10 mg/day prednisone (or equivalent)
Acute infection at the time of inclusion
Refusal or inability to provide informed consent (or assent, when applicable)
Chronic inflammatory lung disease currently treated with immunosuppressive therapy

Treatment and study plan

Peripheral Blood Collection for Immune Profiling

Other

Participants provide biological samples for immune profiling and translational research. Samples include peripheral blood and, when available from routine clinical care, additional specimens such as tumor tissue or rlymph node, bone marrow. No experimental treatments are given. Collected samples are analyzed to characterize immune cell populations and their functional and molecular features, with the aim of studying immune mechanisms involved in lung cancer, sarcoidosis, and COPD, as well as factors associated with disease progression and treatment response. All medical care and treatment decisions remain independent of study participation.

Primary outcomes

Progression free survival

Time frame: Throughout the entire study, approximately during 7 years

median Progression free survival

Study contacts

Contact information is provided by the study sponsor or research team.

Frank Aboubakar Nana, MD; PhD

CONTACT

[email protected]

0032 2 764 85 19

Kim Henquin, Study nurse

CONTACT

[email protected]

0032 2 764 42 26

Sponsors and collaborators

Lead sponsor

Université Catholique de Louvain

Other

Registry information

Acronym: IMMUNOPUMON2

Important dates

Study start: 2025
Primary completion: 2030
Study completion: 2032
First posted: Feb 3, 2026
Registry last updated: Feb 3, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting